A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/565 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2403608
The invention relates to the use of fulvestrant in the treatment of breast cancer in patients who have previously been treated with an Selective Estrogen Receptor Modulator (SERM) and an aromatase inhibitor.
L'invention concerne l'utilisation de fulvestrant dans le traitement du cancer du sein chez des patients ayant préalablement été traités par un modulateur sélectif des récepteurs d'oestrogènes (SERM) et un inhibiteur d'aromatase.
Thurlimann Beat
Astrazeneca Ab
Smart & Biggar
LandOfFree
Use of fulvestrant in the treatment of resistant breast cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of fulvestrant in the treatment of resistant breast cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of fulvestrant in the treatment of resistant breast cancer will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1676407